Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study

Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study

Introduction: The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators and proteasome inhibitors. The bortezomib, thalidomide, and dexamethasone (VTD) and thalidomide and dexamethasone (TD) regimens are commonly used as a first-line treatment due...

Full description

Saved in:

Bibliographic Details
Main Authors:	Juan M. Cano-Calderón, Juan F. Zazueta-Pozos, Adán G. Gallardo-Rodríguez, Carlos Martínez-Murillo, Irma Olarte-Carrillo, Adolfo Martínez-Tovar, Christian O. Ramos-Peñafiel
Format:	Article
Language:	English
Published:	Permanyer 2025-01-01
Series:	Revista Médica del Hospital General de México
Subjects:	Multiple myeloma. Bortezomib. Thalidomide. Acute phase response. Survival.
Online Access:	https://www.hospitalgeneral.mx/frame_eng.php?id=240
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01)

Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
by: Eva Plakoula, et al.
Published: (2025-01-01)

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
by: Quane Zhang, et al.
Published: (2025-01-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2024-12-01)

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01)

Guillain-Barré syndrome in patients with multiple myeloma: three cases report and literature review
by: Zhichao Li, et al.
Published: (2025-01-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
by: Bhanu K. Patibandla, et al.
Published: (2014-01-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Treatment of Coexisting Chronic Neutrophilic Leukemia and Light Chain Multiple Myeloma with Hydroxyurea, Bortezomib, and Dexamethasone
by: Evelyn Taiwo, et al.
Published: (2014-01-01)

Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis
by: Xuejie Gao, et al.
Published: (2025-01-01)

A Novel Green Synthesis of Thalidomide and Analogs
by: Ellis Benjamin, et al.
Published: (2017-01-01)

Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome
by: Hua Bai, et al.
Published: (2025-01-01)

Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
by: Kara I. Cicero, et al.
Published: (2025-01-01)

Effects of Thalidomide on the Expression of Adhesion Molecules in Rat Liver Cirrhosis
Published: (2006-01-01)

Effects of Thalidomide on the Expression of Adhesion Molecules in Rat Liver Cirrhosis
by: Peng Lv, et al.
Published: (2006-01-01)

Single-Agent Thalidomide for Treatment of Malignant Paraganglioma of the Organ of Zuckerkandl
by: Mackenzie L. Shindorf, et al.
Published: (2019-01-01)

Carvacrol attenuated haloperidol-induced Parkinson’s disease via TNF/NFκβ-NLRP3-mediated pyroptosis
by: Faisal Albaqami, et al.
Published: (2025-02-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
by: Ugo Testa, et al.
Published: (2024-10-01)

THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA
by: Kun Yang, et al.
Published: (2024-01-01)

Dramatic Reduction in Tumour Size in Hepatocellular Carcinoma Patients on Thalidomide Therapy
by: Denny Demeria, et al.
Published: (2007-01-01)

Chromothripsis in Treatment Resistance in Multiple Myeloma
by: Kyoung Joo Lee, et al.
Published: (2017-09-01)

EFFECTS OF THALIDOMIDE ON ENDOTHELIAL ACTIVATION AND STRESS INDEX IN CHILDREN WITH Β-THALASSEMIA MAJOR
by: Kun Yang
Published: (2024-10-01)

Multifocal Arterial Thrombosis during Thalidomide Therapy: Case Report and Review of the Literature
by: Monica Ferri, et al.
Published: (2009-01-01)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

Incorporation and Effect of Arachidonic Acid on the Growth of Human Myeloma Cell Lines
by: V. Desplat, et al.
Published: (1999-01-01)

Evaluation of plasma cell sorting methods in multiple myeloma patients: flow cytometry versus magnetic beads
by: Yu Jeong Choi, et al.
Published: (2025-01-01)

Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study
by: Matthew A. Lee, et al.
Published: (2025-01-01)

Prognostic correlation analysis of multiple myeloma based on HALP score of peripheral blood before chemotherapy
by: CHEN Min, et al.
Published: (2025-01-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

Metabolomics approach reveals key plasma biomarkers in multiple myeloma for diagnosis, staging, and prognosis
by: Xiaoxue Wang, et al.
Published: (2025-02-01)

The association between the dietary inflammatory index and multiple myeloma: a case–control study
by: Hoda Zahedi, et al.
Published: (2025-01-01)

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review
by: Hongxia Wang, et al.
Published: (2025-01-01)

Detection of new single nucleotide polymorphisms in plasma cells carcinoma (myeloma) by polymerase chain reaction–single strand conformation polymorphism and sequencing technical methods
by: Sarah K. Obayes, et al.
Published: (2024-01-01)

Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group
by: Anna Waszczuk-Gajda, et al.
Published: (2020-04-01)

Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in US Veterans with rheumatoid arthritis
by: Kate Tokareva, et al.
Published: (2025-01-01)

High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment
by: Halina Urbanska-Rys, et al.
Published: (2003-01-01)

Knowledge, attitude and practice towards multiple myeloma among medical staff in Enshi Region
by: Luping Zou, et al.
Published: (2025-01-01)